close search

Vaginal Live Biotherapeutics for Women’s Sexual and Reproductive Health

Bacterial vaginosis (BV) is a highly prevalent imbalance in the vaginal microbiome that increases risk of HIV acquisition and adverse birth outcomes. BV remains prevalent partly because existing treatment has limited efficacy. We aim to address this healthcare gap by developing more effective therapeutics to improve treatment outcomes.

2016-ongoing

To develop live biotherapeutics for BV treatment in different populations.

A key barrier to optimizing women’s sexual and reproductive health is the lack of effective treatment for BV. BV and the adverse outcomes that this condition causes are associated with significant morbidity, mortality and social and economic costs. Developing effective treatment options would improve the quality of life of women who have recurrent BV and has the potential to reduce the rates of infertility, acquisition of sexually transmitted infections including HIV, spontaneous preterm birth, and other adverse birth outcomes. 

Contact Person

Contact Doctor Lindi Masson for more information about this project.

EMAIL

Funding
Partners

  • ACH4
  • South African Medical Research Council
  • NHMRC

Partners +
Collaborators

  • University of Cape Town, South Africa
  • Desmond Tutu Health Foundation, South Africa
  • Melbourne Sexual Health Centre

Project Team

Meet the project team. Together, we are translating research into better health, for all.